UK Pharma Companies Face £45 million in Pay-For-Delay Deal Fines
February 22, 2016.
The Competition and Markets Authority (CMA), a UK-based non-ministerial department monitoring market competition, has fined multiple pharmaceutical companies £45 million ($64.3 million) for pay-for-delay deals.
CMA says these deals “potentially deprived the National Health Service of the significant price falls that generally result from generic competition.” Chapter I prohibition of the Competition Act of 1998 prohibits these methods of competition restriction. A company found in violation of this act can face fines of up to 10% of its worldwide turnover.
See more on this story here at Pharmaceutical Technology.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
